{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T06:27:51Z","timestamp":1772864871041,"version":"3.50.1"},"reference-count":55,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2022,3,12]],"date-time":"2022-03-12T00:00:00Z","timestamp":1647043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"La ligue contre le cancer","award":["NA"],"award-info":[{"award-number":["NA"]}]},{"name":"Fujirebio (Japan)","award":["NA"],"award-info":[{"award-number":["NA"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Background: Analysis of serum biomarkers for the assessment of atrophic gastritis (AG), a gastric precancerous lesion, is of growing interest for identification of patients at increased risk of gastric cancer. The aim was to analyze the diagnostic performance of serum pepsinogen testing using another method, chemiluminescent enzyme immunoassay (CLEIA), as well as of other new potential biomarkers. Material and Methods: The sera of patients considered at increased risk of gastric cancer and undergoing upper endoscopy collected in our previous prospective, multicenter study were tested for pepsinogen I (PGI) and II (PGII), interleukin-6 (IL-6), human epididymal protein 4 (HE-4), adiponectin, ferritin and Krebs von den Lungen (KL-6) using the CLEIA. The diagnostic performance for the detection of AG was calculated by taking histology as the reference. Results: In total, 356 patients (162 men (46%); mean age 58.6 (\u00b114.2) years), including 152 with AG, were included. For the detection of moderate to severe corpus AG, sensitivity and specificity of the pepsinogen I\/II ratio were of 75.0% (95%CI 57.8\u201387.9) and 92.6% (88.2\u201395.8), respectively. For the detection of moderate to severe antrum AG, sensitivity of IL-6 was of 72.2% (95%CI 46.5\u201390.3). Combination of pepsinogen I\/II ratio or HE-4 showed a sensitivity of 85.2% (95%CI 72.9\u201393.4) for the detection of moderate to severe AG at any location. Conclusion: This study shows that PG testing by CLEIA represents an accurate assay for the detection of corpus AG. Additionally, IL-6 and HE-4 may be of interest for the detection of antrum AG. Mini-abstract: Pepsinogens testing by chemiluminescent enzyme immunoassay is accurate for the detection of corpus atrophic gastritis. IL-6 and HE-4 maybe of interest for the detection of antrum atrophic gastritis.<\/jats:p>","DOI":"10.3390\/diagnostics12030695","type":"journal-article","created":{"date-parts":[[2022,3,13]],"date-time":"2022-03-13T22:29:43Z","timestamp":1647210583000},"page":"695","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Serum Pepsinogens Combined with New Biomarkers Testing Using Chemiluminescent Enzyme Immunoassay for Non-Invasive Diagnosis of Atrophic Gastritis: A Prospective, Multicenter Study"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-9693","authenticated-orcid":false,"given":"Nicolas","family":"Chapelle","sequence":"first","affiliation":[{"name":"IMAD, Hepato-Gastroenterology & Digestive Oncology, University Hospital of Nantes, H\u00f4tel Dieu, Place Alexis Ricordeau, CEDEX 1, 44093 Nantes, France"},{"name":"INSERM U1064 CRTI, 44093 Nantes, France"},{"name":"Faculty of Medicine, University of Nantes, 44300 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6188-7328","authenticated-orcid":false,"given":"Malgorzata","family":"Osmola","sequence":"additional","affiliation":[{"name":"Department of Immunology, University Hospital of Nantes, 44093 Nantes, France"},{"name":"Department of Hematology, Transplantation and Internal Medicine, Medical University, 02-091 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0068-8776","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"Martin","sequence":"additional","affiliation":[{"name":"INSERM U1064 CRTI, 44093 Nantes, France"},{"name":"Faculty of Medicine, University of Nantes, 44300 Nantes, France"},{"name":"Department of Immunology, University Hospital of Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Blin","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nantes, 44300 Nantes, France"},{"name":"Department of Biochemistry, University Hospital of Nantes, 44093 Nantes, France"},{"name":"INSERM U1235 TENS, 44300 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maxime","family":"Leroy","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, CHU de Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iva","family":"Jirka","sequence":"additional","affiliation":[{"name":"IMAD, Hepato-Gastroenterology & Digestive Oncology, University Hospital of Nantes, H\u00f4tel Dieu, Place Alexis Ricordeau, CEDEX 1, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Driffa","family":"Moussata","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, University Hospital of Tours, 37044 Tours, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominique","family":"Lamarque","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, Ambroise-Par\u00e9 Hospital, AP-HP, Paris Saclay University, UVSQ, INSERM, Infection and Inflammation, 91190 Paris, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raphael","family":"Olivier","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, Poitiers University Hospital, University of Poitiers, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8065-9635","authenticated-orcid":false,"given":"David","family":"Tougeron","sequence":"additional","affiliation":[{"name":"Department of Hepato-Gastroenterology, Poitiers University Hospital, University of Poitiers, 86000 Poitiers, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Hay-Lombardie","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University Hospital of Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edith","family":"Bigot-Corbel","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nantes, 44300 Nantes, France"},{"name":"Department of Biochemistry, University Hospital of Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2056-4730","authenticated-orcid":false,"given":"Damien","family":"Masson","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nantes, 44300 Nantes, France"},{"name":"Department of Biochemistry, University Hospital of Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Fran\u00e7ois","family":"Mosnier","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Nantes, 44300 Nantes, France"},{"name":"Department of Pathology, University Hospital of Nantes, 44093 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tamara","family":"Matysiak-Budnik","sequence":"additional","affiliation":[{"name":"IMAD, Hepato-Gastroenterology & Digestive Oncology, University Hospital of Nantes, H\u00f4tel Dieu, Place Alexis Ricordeau, CEDEX 1, 44093 Nantes, France"},{"name":"INSERM U1064 CRTI, 44093 Nantes, France"},{"name":"Faculty of Medicine, University of Nantes, 44300 Nantes, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,3,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1136\/gutjnl-2019-320234","article-title":"Is gastric cancer becoming a rare disease? A global assessment of predicted incidence trends to 2035","volume":"69","author":"Arnold","year":"2020","journal-title":"Gut"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3322\/caac.21492","article-title":"Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries: Global Cancer Statistics 2018","volume":"68","author":"Bray","year":"2018","journal-title":"CA. Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1007\/s10120-015-0548-2","article-title":"Erratum to: Trends in gastric cancer incidence: A period and birth cohort analysis in a well-defined French population","volume":"19","author":"Chapelle","year":"2016","journal-title":"Gastric Cancer"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1245\/s10434-016-5279-z","article-title":"Early Gastric Cancer: Trends in Incidence, Management, and Survival in a Well-Defined French Population","volume":"23","author":"Chapelle","year":"2016","journal-title":"Ann. Surg. Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0140-6736(75)90498-5","article-title":"A model for gastric cancer epidemiology","volume":"2","author":"Correa","year":"1975","journal-title":"Lancet Lond. Engl."},{"key":"ref_6","first-page":"3554","article-title":"A human model of gastric carcinogenesis","volume":"48","author":"Correa","year":"1988","journal-title":"Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1053\/j.gastro.2008.01.071","article-title":"Gastric cancer risk in patients with premalignant gastric lesions: A nationwide cohort study in the Netherlands","volume":"134","author":"Looman","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"h3867","DOI":"10.1136\/bmj.h3867","article-title":"Incidence of gastric cancer among patients with gastric precancerous lesions: Observational cohort study in a low risk Western population","volume":"351","author":"Song","year":"2015","journal-title":"BMJ"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1159\/000503748","article-title":"Prevalence, Characteristics and Endoscopic Management of Gastric Premalignant Lesions in France","volume":"38","author":"Chapelle","year":"2020","journal-title":"Dig. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1055\/s-0032-1326379","article-title":"Follow-up of premalignant lesions in patients at risk for progression to gastric cancer","volume":"45","author":"Holster","year":"2013","journal-title":"Endoscopy"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1136\/gutjnl-2017-314498","article-title":"Surveillance of premalignant gastric lesions: A multicentre prospective cohort study from low incidence regions","volume":"68","author":"Holster","year":"2019","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"405","DOI":"10.2183\/pjab.87.405","article-title":"Gastric cancer screening by combined assay for serum anti-Helicobacter pylori IgG antibody and serum pepsinogen levels\u2014\u201cABC method\u201d","volume":"87","author":"Miki","year":"2011","journal-title":"Proc. Jpn. Acad. Ser. B Phys. Biol. Sci."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1055\/a-0859-1883","article-title":"Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019","volume":"51","author":"Areia","year":"2019","journal-title":"Endoscopy"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1080\/00365520802273025","article-title":"Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study","volume":"43","author":"Storskrubb","year":"2008","journal-title":"Scand. J. Gastroenterol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"5133","DOI":"10.21873\/anticanres.11083","article-title":"A Panel of Serum Biomarkers (GastroPanel\u00ae) in Non-invasive Diagnosis of Atrophic Gastritis. Systematic Review and Meta-analysis","volume":"36","year":"2016","journal-title":"Anticancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e12727","DOI":"10.1111\/hel.12727","article-title":"A panel of stomach-specific biomarkers (GastroPanel\u00ae) for the diagnosis of atrophic gastritis: A prospective, multicenter study in a low gastric cancer incidence area","volume":"25","author":"Chapelle","year":"2020","journal-title":"Helicobacter"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1038\/sj.bjc.6603051","article-title":"Adiponectin and cancer: A systematic review","volume":"94","author":"Kelesidis","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_18","first-page":"220","article-title":"Clinicopathology of sialomucin: MUC1, particularly KL-6 mucin, in gastrointestinal, hepatic and pancreatic cancers","volume":"3","author":"Inagaki","year":"2009","journal-title":"Biosci. Trends"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.bbrc.2017.01.110","article-title":"TNF-\u03b1-inducing protein of Helicobacter pylori induces epithelial-mesenchymal transition (EMT) in gastric cancer cells through activation of IL-6\/STAT3 signaling pathway","volume":"484","author":"Chen","year":"2017","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1053\/j.gastro.2007.11.058","article-title":"A Molecular Signature of Gastric Metaplasia Arising in Response to Acute Parietal Cell Loss","volume":"134","author":"Nozaki","year":"2008","journal-title":"Gastroenterology"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1097\/00000478-199610000-00001","article-title":"Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994","volume":"20","author":"Dixon","year":"1996","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Osumi, H., Fujisaki, J., Suganuma, T., Horiuchi, Y., Omae, M., Yoshio, T., Ishiyama, A., Tsuchida, T., and Miki, K. (2017). A significant increase in the pepsinogen I\/II ratio is a reliable biomarker for successful Helicobacter pylori eradication. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183980"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1473","DOI":"10.2169\/internalmedicine.3521-19","article-title":"Usefulness and Limitations of a Serum Screening System to Predict the Risk of Gastric Cancer","volume":"59","author":"Kishino","year":"2020","journal-title":"Intern. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/apt.14248","article-title":"Systematic review with meta-analysis: Diagnostic performance of the combination of pepsinogen, gastrin-17 and anti- Helicobacter pylori antibodies serum assays for the diagnosis of atrophic gastritis","volume":"46","author":"Zagari","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13317-017-0097-2","article-title":"Chemiluminescent immunoassay technology: What does it change in autoantibody detection?","volume":"8","author":"Cinquanta","year":"2017","journal-title":"Autoimmun. Highlights"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e12393","DOI":"10.1111\/hel.12393","article-title":"Detection of gastric atrophy by circulating pepsinogens: A comparison of three assays","volume":"22","author":"Leja","year":"2017","journal-title":"Helicobacter"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1136\/gutjnl-2016-311685","article-title":"Dynamics of Helicobacter pylori infection as a determinant of progression of gastric precancerous lesions: 16-year follow-up of an eradication trial","volume":"67","author":"Mera","year":"2018","journal-title":"Gut"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"e00237","DOI":"10.14309\/ctg.0000000000000237","article-title":"Long-Term Follow-up of Gastric Precancerous Lesions in a Low GC Incidence Area","volume":"11","author":"Chapelle","year":"2020","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1111\/jgh.13249","article-title":"Incomplete type of intestinal metaplasia has the highest risk to progress to gastric cancer: Results of the Spanish follow-up multicenter study: Incomplete type of intestinal metaplasia","volume":"31","author":"Companioni","year":"2016","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1136\/jcp.2003.11270","article-title":"A follow up model for patients with atrophic chronic gastritis and intestinal metaplasia","volume":"57","author":"Lopes","year":"2004","journal-title":"J. Clin. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"145","DOI":"10.2478\/v10039-011-0040-0","article-title":"Value of gastrin-17 in detecting antral atrophy","volume":"56","author":"Leja","year":"2011","journal-title":"Adv. Med. Sci."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.beem.2013.08.006","article-title":"Adiponectin as a routine clinical biomarker","volume":"28","author":"Kishida","year":"2014","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1158\/1078-0432.466.11.2","article-title":"Plasma adiponectin and gastric cancer","volume":"11","author":"Ishikawa","year":"2005","journal-title":"Clin. Cancer Res. Off. J. Am. Assoc. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1078\/0344-0338-00318","article-title":"Expression of MUC1 and MUC2 Mucins in Gastric Carcinomas: Their Relationship with Clinicopathologic Parameters and Prognosis","volume":"198","author":"Akyol","year":"2002","journal-title":"Pathol. Res. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Kim, D.-K., Oh, S.Y., Kwon, H.-C., Lee, S., Kwon, K.A., Kim, B.G., Kim, S.-G., Kim, S.-H., Jang, J.S., and Kim, M.C. (2009). Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer. BMC Cancer, 9.","DOI":"10.1186\/1471-2407-9-155"},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"S\u00e1nchez-Zauco, N., Torres, J., G\u00f3mez, A., Camorlinga-Ponce, M., Mu\u00f1oz-P\u00e9rez, L., Herrera-Goepfert, R., Medrano-Guzm\u00e1n, R., Giono-Cerezo, S., and Maldonado-Bernal, C. (2017). Circulating blood levels of IL-6, IFN-\u03b3, and IL-10 as potential diagnostic biomarkers in gastric cancer: A controlled study. BMC Cancer, 17.","DOI":"10.1186\/s12885-017-3657-y"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"29820","DOI":"10.18632\/oncotarget.25661","article-title":"Systematic literature review of IL-6 as a biomarker or treatment target in patients with gastric, bile duct, pancreatic and colorectal cancer","volume":"9","author":"Vainer","year":"2018","journal-title":"Oncotarget"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1007\/s13277-014-2858-0","article-title":"The human epididymis protein 4 acts as a prognostic factor and promotes progression of gastric cancer","volume":"36","author":"Guo","year":"2015","journal-title":"Tumor Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.humpath.2012.07.017","article-title":"Human epididymis protein 4 is up-regulated in gastric and pancreatic adenocarcinomas","volume":"44","author":"Nam","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"G777","DOI":"10.1152\/ajpgi.00169.2014","article-title":"Establishment of novel in vitro mouse chief cell and SPEM cultures identifies MAL2 as a marker of metaplasia in the stomach","volume":"307","author":"Weis","year":"2014","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10552-012-0106-8","article-title":"The utility of serologic tests as biomarkers for Helicobacter pylori-associated precancerous lesions and gastric cancer varies between Latin American countries","volume":"24","author":"Kasamatsu","year":"2013","journal-title":"Cancer Causes Control"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/apt.14082","article-title":"The risk of gastric cancer in patients with gastric intestinal metaplasia in 5-year follow-up","volume":"46","author":"Pittayanon","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1443-1661.2009.00845.x","article-title":"Cautious comparison between East and West is necessary in terms of the serum pepsinogen test","volume":"21","author":"Miki","year":"2009","journal-title":"Dig. Endosc."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1158\/1055-9965.EPI-05-0931","article-title":"Prevalence of Chronic Atrophic Gastritis in Different Parts of the World","volume":"15","author":"Weck","year":"2006","journal-title":"Cancer Epidemiol. Biomarkers Prev."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s10620-015-3591-2","article-title":"High Prevalence of Gastric Preneoplastic Lesions in East Asians and Hispanics in the USA","volume":"60","author":"Choi","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/j.gie.2017.11.010","article-title":"Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a U.S. population","volume":"87","author":"Choi","year":"2018","journal-title":"Gastrointest. Endosc."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1016\/j.ejca.2010.12.012","article-title":"The prevalence of premalignant gastric lesions in asymptomatic patients: Predicting the future incidence of gastric cancer","volume":"47","author":"Capelle","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1002\/ijc.2910570306","article-title":"Intestinal metaplasia types and the risk of gastric cancer: A cohort study in Slovenia","volume":"57","author":"Filipe","year":"1994","journal-title":"Int. J. Cancer"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1007\/s00535-011-0504-9","article-title":"Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication","volume":"47","author":"Kodama","year":"2012","journal-title":"J. Gastroenterol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"e183","DOI":"10.1038\/ctg.2016.42","article-title":"Pepsinogens to Distinguish Patients With Gastric Intestinal Metaplasia and Helicobacter pylori Infection Among Populations at Risk for Gastric Cancer","volume":"7","author":"Orzes","year":"2016","journal-title":"Clin. Transl. Gastroenterol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1111\/j.1440-1746.2010.06413.x","article-title":"Correlation of serum pepsinogens and gastrin-17 with atrophic gastritis in gastroesophageal reflux patients: A matched-pairs study","volume":"26","author":"Peitz","year":"2011","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1097\/00042737-200308000-00009","article-title":"Non-endoscopic diagnosis of atrophic gastritis with a blood test. Correlation between gastric histology and serum levels of gastrin-17 and pepsinogen I: A multicentre study","volume":"15","author":"Vauhkonen","year":"2003","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/ijc.28003","article-title":"Utility of subtyping intestinal metaplasia as marker of gastric cancer risk. A review of the evidence: Subtypes of intestinal metaplasia and gastric cancer risk","volume":"133","author":"Gisbert","year":"2013","journal-title":"Int. J. Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1053\/j.gastro.2020.11.017","article-title":"The Colombian Chemoprevention Trial: 20-Year Follow-Up of a Cohort of Patients With Gastric Precancerous Lesions","volume":"160","author":"Piazuelo","year":"2021","journal-title":"Gastroenterology"},{"key":"ref_55","first-page":"101735","article-title":"Cost-effectiveness of prevention and early detection of gastric cancer in Western countries","volume":"50\u201351","author":"Meester","year":"2021","journal-title":"Best Pract. Res. Clin. Gastroenterol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/3\/695\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T22:35:29Z","timestamp":1760135729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/12\/3\/695"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,12]]},"references-count":55,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,3]]}},"alternative-id":["diagnostics12030695"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics12030695","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,12]]}}}